Biopharma R&D laboratory design
Key Statistics
Client
EMD Serono
Year
Current
PM Group Office
US East Coast
Cost
$57m USD
Size
145,000 sqft

EMD Serono is expanding its US biopharmaceutical R&D laboratory facility in Billerica, MA to advance it’s innovative clinical pipeline in oncology, immuno-oncology and immunology.

Do you have a pharmaceutical project? Talk to one of our experts.

Andy Rayner
Andy Rayner

Pharmaceutical Sector Director

A mixed use development

PM Group’s architects are designing this new 145,000 sq ft mixed use office and R&D laboratories development. It incorporates a central campus cafeteria and is connected to existing adjacent facilities via a bridge. The building is being designed to LEED Gold and WELL 2.0 standard. Construction is due to be completed in 2021.

About the WELL Standard

WELL 2.0 is the WELL Building Institute’s evidence-based system for measuring, certifying and monitoring building performance features that address well-being of users.

The WELL Building Standard/ WELL V2 is the leading performance standard for health and wellness in the built environment, It incorporates 10 concepts including Air, Water, Nourishment, Light, Movement, Thermal Comfort, Sound, Materials, Mind and Community.

WELL focuses exclusively on the health and wellness of building occupants taking a holistic approach in the built environment addressing behavior, operations and design, and is intended to promote health, happiness and productivity of employees.

About EMD Serono

EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada. The company is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and multiple sclerosis. EMD Serono continues to strengthen its innovation footprint in both the U.S. and Darmstadt, Germany where it’s global R&D headquarters are located, with the goal of delivering transformational value to patients around the world.

 

Andy Rayner

Pharmaceutical Sector Director